18 F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors

Leukemia & Lymphoma
Angelo CastelloEgesta Lopci

Abstract

Our aim was to evaluate Hodgkin Lymphoma (HL) response to checkpoint inhibitors with 18F-FDG PET/CT. Forty three refractory or relapsed HL patients were investigated before immunotherapy, 8 weeks and 17 weeks after administration of either nivolumab or pembrolizumab. The median follow-up was 19 months. Best clinical response was complete response (CR) in 26 patients, partial response (PR) in 5 patients, stable disease (SD) in 8 patients, and progression disease (PD) in 4 patients. At the early assessment, Deauville Score (DS) resulted significantly different in responder group compared to nonresponders. SUVmax was significantly lower in responders, while there was no relevant modification in the tumor burden. At interim evaluation, DS well differentiated responder group. A significant decrease in glucose metabolism and tumor burden parameters was observed in responder patients, who presented with a longer progression-free survival then nonresponders. 18F-FDG PET/CT provides a reliable indication of treatment response under checkpoints inhibitors, even at an early assessment.

References

Feb 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H YoungP Price
Sep 18, 2007·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Chieh LinMichel Meignan
Sep 24, 2008·Proceedings of the National Academy of Sciences of the United States of America·Shawn D BlackburnE John Wherry
Jun 24, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Richard L WahlMartin A Lodge
Jun 23, 2009·Leukemia & Lymphoma·Michel MeignanCorinne Haioun
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Dec 17, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Michal Weiler-SagieOra Israel
Sep 8, 2010·The New England Journal of Medicine·Andreas EngertVolker Diehl
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian SteidlRandy D Gascoyne
Oct 12, 2013·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Eva M Palsson-McDermott, Luke A J O'Neill
Mar 8, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Dirk HasencleverRegine Kluge
Jun 24, 2014·American Journal of Hematology·Stephen M Ansell
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Dec 3, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Ronald BoellaardUNKNOWN European Association of Nuclear Medicine (EANM)
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Apr 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaretha G M RoemerMargaret A Shipp
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandCraig H Moskowitz
Mar 9, 2017·The Lancet Oncology·Lesley SeymourUNKNOWN RECIST working group
Apr 1, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Steve Y ChoRichard L Wahl
Apr 1, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Katja PinkerWolfgang A Weber
Apr 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert ChenUNKNOWN KEYNOTE-087
Jun 10, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Laurent DercleJean-Marie Michot
Aug 18, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Sabrina RossiEgesta Lopci

❮ Previous
Next ❯

Citations

Nov 30, 2018·Frontiers in Oncology·Christopher ChinNagi G Ayad
Sep 15, 2020·Annals of Nuclear Medicine·Juan Carlos Prieto PrietoChrissa Sioka
Oct 10, 2020·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Roberto García-FigueirasJoan C Vilanova
Oct 31, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Conrad-Amadeus VoltinPaul J Bröckelmann
Nov 18, 2020·European Radiology Experimental·Marcus UnterrainerClemens C Cyran
Apr 4, 2021·Journal of Personalized Medicine·Cristina FerrariGiuseppe Rubini
Nov 19, 2019·PET Clinics·Egesta Lopci, Michel Meignan
Dec 7, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Giovanni RossiFrancesco Grossi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.